首页 | 本学科首页   官方微博 | 高级检索  
     


A phase 2 study of glembatumumab vedotin,an antibody-drug conjugate targeting glycoprotein NMB,in patients with advanced melanoma
Authors:Patrick A. Ott MD  PhD  Anna C. Pavlick DO  Douglas B. Johnson MD  Lowell L. Hart MD  Jeffrey R. Infante MD  Jason J. Luke MD  Jose Lutzky MD  Neal E. Rothschild MD  Lynn E. Spitler MD  C. Lance Cowey MD  Aaron R. Alizadeh MD  April K. Salama MD  Yi He PhD  Thomas R. Hawthorne PhD  Rebecca G. Bagley MA  Joshua Zhang MD  PhD  Christopher D. Turner MD  Omid Hamid MD
Affiliation:1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts;2. Department of Medical Oncology, New York University School of Medicine, New York, New York;3. Department of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee;4. Florida Cancer Specialists and Research Institute, Fort Myers, Florida;5. Tennessee Oncology, PLLC, Nashville, Tennessee;6. Department of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois;7. Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida;8. Florida Cancer Specialists, West Palm Beach, Florida;9. St. Mary's Medical Center, San Francisco, California;10. Northern California Melanoma Center, Baylor University Medical Center, Dallas, Texas;11. Northside Hospital Cancer Institute, Decatur, Georgia;12. Department of Medical Oncology, Duke University, Durham, North Carolina;13. Celldex Therapeutics, Inc, Hampton, New Jersey;14. The Angeles Clinic and Research Institute, Los Angeles, California
Abstract:
Keywords:antibody-drug conjugate  clinical trial  phase 2  glembatumumab vedotin  glycoprotein NMB (gpNMB)  melanoma  targeted therapy
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号